Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 7/20 | 0.37 |
| ▸ | ACKR3 | P25106 | 4/20 | 0.36 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.35 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16898465 | 1.00 | USP2 (0.38) | USP2SMN1; SMN2CHRM2CHRM1CHRM4 | |
| SCHEMBL16898400 | 1.00 | USP2 (0.38) | USP2SMN1; SMN2CHRM2CHRM1CHRM4 | |
| SCHEMBL16898385 | 1.00 | USP2 (0.38) | USP2SMN1; SMN2CHRM2CHRM1CHRM4 | |
| SCHEMBL16898492 | 0.99 | USP2 (0.39) | USP2SMN1; SMN2CHRM2CHRM1CHRM4 | |
| SCHEMBL16906830 | 0.90 | USP2 (0.38) | USP2SMN1; SMN2CHRM2CHRM1CHRM4 | |
| SCHEMBL23301354 | 0.87 | TLR8 (0.42) | USP2SMN1; SMN2CHRM2CHRM1CHRM4 | |
| SCHEMBL14270252 | 0.87 | USP2 (0.47) | USP2SMN1; SMN2CHRM2CHRM1CHRM4 | |
| SCHEMBL16899896 | 0.86 | TLR8 (0.34) | CHRM2CHRM1CHRM4CHRM3TLR8 | |
| SCHEMBL16899897 | 0.84 | EPHX2 (0.33) | TLR8EPHX2ACKR3DDB1CRBN | |
| SCHEMBL16899915 | 0.84 | MMP2 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250144253-A1 | 3-((3-([1,1'-BIPHENYL]-3-YLMETHOXY)PHENOXY)METHYL)BENZONITRILE DERIVATIVES AND THE USE THEREOF | HELMHOLTZ-ZENTRUM DRESDEN-ROSSENDORF E.V. (DE) | 2025-05-08 | — | — | US | disclosed |
| EP-4444423-A1 | 3-((3-([1,1'-BIPHENYL]-3-YLMETHOXY)PHENOXY)METHYL)BENZONITRILE DERIVATIVES AND THE USE THEREOF | Helmholtz-Zentrum Dresden - Rossendorf e.V. (DE) | 2024-10-16 | — | — | EP | disclosed |
| WO-2023104744-A1 | 3-((3-([1,1'-BIPHENYL]-3-YLMETHOXY)PHENOXY)METHYL)BENZONITRILE DERIVATIVES AND THE USE THEREOF | HELMHOLTZ-ZENTRUM DRESDEN-ROSSENDORF E.V. (DE) | 2023-06-15 | — | — | WO | disclosed |
| WO-2015106292-A1 | BCR-ABL TYROSINE-KINASE LIGANDS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME | COFERON, INC. (US) | 2015-07-16 | — | — | WO | disclosed |
| WO-2015106292-A1 | BCR-ABL TYROSINE-KINASE LIGANDS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME | COFERON, INC. (US) | 2015-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250144253-A1 | 3-((3-([1,1'-BIPHENYL]-3-YLMETHOXY)PHENOXY)METHYL)BENZONITRILE DERIVATIVES AND THE USE THEREOF | CYP4B1, UGT2B7, UGT1A4 | USP2 2080/4885SMN1; SMN2 2311/4885CHRM2 2470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.